News | May 29, 2022
Venus Remedies registers 9.22 % growth in annual sales for FY22
The company’s annual sales grew from Rs 548.12 crore in FY 2020-21 to Rs 598.65 crore this fiscal
The company’s annual sales grew from Rs 548.12 crore in FY 2020-21 to Rs 598.65 crore this fiscal
JB, in its new avatar, emerges as the fastest growing pharmaceuticals company in India
The integration and transition of the brands are expected to be completed by June 2022.
Lung cancer is the leading cause of cancer death in the USA, making up almost 25% of all cancer deaths
Perrigo expects to launch Omeprazole Minis later this year
The centre works with active pharmaceutical ingredients (APIs) and can utilize innovative concepts with model APIs
The acquisition is subject to customary closing conditions and necessary regulatory approvals. The financial terms of the transaction are confidential
Pemetrexed for Injection has a market size of USD 1,236 mn (as per IQVIA MAT March’22)
The AI and technology upgrades allow doctors to choose their medical speciality and even spelling preferences to set their own speech model
ICICI Direct expects revenue CAGR of 35.6% over FY22-FY24E mainly due to the consolidation of Viatris business and they expect EBITDA margin expansion of 230bps and earnings CAGR of 64.8% over FY22-FY24E
Subscribe To Our Newsletter & Stay Updated
